UK Markets close in 6 hrs 30 mins

BRIEF-Morphosys, I-Mab Sign Agreement For Morphosys's Novel Immuno-Oncology Agent MOR210

Nov 16 (Reuters) - MorphoSys AG:

* DGAP-NEWS: MORPHOSYS AND I-MAB SIGN STRATEGIC PARTNERING AGREEMENT FOR MORPHOSYS'S NOVEL IMMUNO-ONCOLOGY AGENT MOR210

* MORPHOSYS -UNDER TERMS OF AGREEMENT, I-MAB WILL EXERCISE ITS EXCLUSIVE LICENSE RIGHTS FOR DEVELOPMENT, COMMERCIALIZATION OF MOR210 IN ITS TERRITORIES

* MORPHOSYS WILL RECEIVE AN UPFRONT PAYMENT OF $3.5 MILLION FROM I-MAB

* MORPHOSYS- I-MAB TO HAVE EXCLUSIVE RIGHTS TO DEVELOP, COMMERCIALIZE MOR210 IN CHINA, HONG KONG, MACAO, TAIWAN, SOUTH KOREA Source text for Eikon: Further company coverage: